Microba Life Sciences Limited (MAP) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. I'm very pleased to share an update on our progress following close of the quarter ended 31 March 2025. And for anyone new to Microba, after the quarterly update here, I'll zoom out and provide an overview of Microba's business. So if you're new, hold on and wait to that for the end. This is our standard disclaimer. I will move past that. So let me start by taking you through the strong numbers from the quarter. And that starts with our delivery of 240% year-on-year growth for our core diagnostic tests. So in Australia, we saw record months across the quarter for MetaExplore continuing to drive growth in test volume. And we just released yesterday in a press release landmark clinical study results for our MetaPanel test in inflammatory bowel disease patients. And that we signed a partnership with a major gastroenterology service provider to embed our testing into routine care. And in the UK, we made great progress in migrating from our legacy testing products there to our focus on Meta Explore, delivering strong month-on-month growth across the quarter, culminating in over 98% growth between Feb and March. And to exemplify that migration from legacy products in the UK, you just have to look at this chart. So firstly, what you can see is sales starting to take off. And second, you can see here on the other axis that we've already replaced around 40% of the legacy GI test sales with Meta Explore over just a handful of months. And so this has been achieved, remember, just through the early access program to a select group of clinicians. And at the end of the quarter, the UK team had built a significant wait list of clinicians eager to access our market-leading product here. So safe to say we're excited about what Q4 will deliver in the UK. And a quick r...